These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9294117)

  • 1. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity.
    Kang YJ; Chen Y; Yu A; Voss-McCowan M; Epstein PN
    J Clin Invest; 1997 Sep; 100(6):1501-6. PubMed ID: 9294117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice.
    Kang YJ; Chen Y; Epstein PN
    J Biol Chem; 1996 May; 271(21):12610-6. PubMed ID: 8647872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
    Wu HY; Kang YJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity.
    Jing L; Wu Y; Wu J; Zhao J; Zuo D; Peng S
    Eur J Pharmacol; 2011 Jun; 659(2-3):224-32. PubMed ID: 21463615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X; Zhou Z; Kang YJ
    Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant status in the liver of hypertensive and metallothionein-deficient mice.
    Bobillier-Chaumont S; Nicod L; Richert L; Berthelot A
    Can J Physiol Pharmacol; 2003 Oct; 81(10):929-36. PubMed ID: 14608409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior increase in metallothionein levels is required to prevent doxorubicin cardiotoxicity.
    Sun X; Kang YJ
    Exp Biol Med (Maywood); 2002 Sep; 227(8):652-7. PubMed ID: 12192109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.
    Hassan MH; El-Beshbishy HA; Aly H; Attia SM; Bahashwan SA; Ghobara MM
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):559-69. PubMed ID: 25053391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic administration of doxorubicin on myocardial creatine phosphokinase and antioxidant defenses and levels of lipid peroxidation in tissues and plasma of rats.
    Robison TW; Giri SN; Wilson DW
    J Biochem Toxicol; 1989; 4(2):87-94. PubMed ID: 2593135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy.
    Gustafson DL; Swanson JD; Pritsos CA
    Free Radic Res Commun; 1993; 19(2):111-20. PubMed ID: 8225037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels.
    Wang GW; Kang YJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):938-44. PubMed ID: 10027829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway.
    Guo J; Guo Q; Fang H; Lei L; Zhang T; Zhao J; Peng S
    Eur J Pharmacol; 2014 Aug; 737():117-24. PubMed ID: 24858368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
    Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
    Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
    Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using MT(-/-) mice to study metallothionein and oxidative stress.
    Conrad CC; Grabowski DT; Walter CA; Sabia M; Richardson A
    Free Radic Biol Med; 2000 Feb; 28(3):447-62. PubMed ID: 10699757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mice overexpressing metallothionein are not resistant to adriamycin cardiotoxicity.
    DiSilvestro RA; Liu J; Klaassen CD
    Res Commun Mol Pathol Pharmacol; 1996 Aug; 93(2):163-70. PubMed ID: 8884987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2.
    Diotte NM; Xiong Y; Gao J; Chua BH; Ho YS
    Biochim Biophys Acta; 2009 Feb; 1793(2):427-38. PubMed ID: 19038292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunocytochemical localization of metallothionein and its relation to doxorubicin toxicity in transgenic mouse heart.
    Zhou Z; Kang YJ
    Am J Pathol; 2000 May; 156(5):1653-62. PubMed ID: 10793076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.
    Doroshow JH; Locker GY; Myers CE
    J Clin Invest; 1980 Jan; 65(1):128-35. PubMed ID: 7350193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.